homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


Subscriber content preview

September 29, 2022

Alzheimer's drug shows promise

CAMBRIDGE, Mass. (AP) — Shares of Biogen and other drugmakers researching Alzheimer's disease have soared after Japan's Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer's. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.


 
. . .


To read this story in full login or purchase a subscription.




Email or user name:
Password:
 
Forgot password? Click here.